Trials / Completed
CompletedNCT02582632
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b (GT1b) hepatitis C virus (HCV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ombitasvir/paritaprevir/ritonavir | Tablet |
| DRUG | dasabuvir | Tablet |
Timeline
- Start date
- 2015-11-24
- Primary completion
- 2016-08-24
- Completion
- 2016-12-01
- First posted
- 2015-10-21
- Last updated
- 2021-07-30
- Results posted
- 2017-12-13
Source: ClinicalTrials.gov record NCT02582632. Inclusion in this directory is not an endorsement.